Related references
Note: Only part of the references are listed.Risk sharing in managed entry agreements-A review of the Swedish experience
Emelie Andersson et al.
HEALTH POLICY (2020)
Managed Entry Agreements: Policy Analysis From the European Perspective
Monique Dabbous et al.
VALUE IN HEALTH (2020)
Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?
Andy Eunwoo Kim et al.
CLINICAL DRUG INVESTIGATION (2020)
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies
Sissel Michelsen et al.
FRONTIERS IN PHARMACOLOGY (2020)
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
Bengt Jonsson et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
Robert Hettle et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
Kim Pauwels et al.
FRONTIERS IN PHARMACOLOGY (2017)
MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY
Simona Montilla et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2015)
THE ITALIAN 648/96 LIST: APPROVALS, REJECTIONS AND METHODS IN AIFA'S EVALUATION PROCESS BETWEEN JANUARY 2013 AND MAY 2015
M. Prada et al.
VALUE IN HEALTH (2015)
Share Paper
